Bellevue Group AG

BBN.SW

Asset Management · Financial Services

Also trades as: 0QLZ.L

Price

CHF 7.40

-0.04 (-0.54%)

Market Cap

CHF 99.0M

Exchange

SIX Swiss Exchange

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Data as of Aug 10, 2026 · filings through Jun 30, 2026

Bellevue Group AG is a Swiss asset management firm that runs investment funds for wealthy individuals and institutional clients like pension funds. The company specializes in healthcare and biotech investing, meaning it pools money from investors and puts it into stocks of hospitals, drug companies, and medical device makers. It is a small, focused player headquartered in Küsnacht, Switzerland.

Bellevue makes money by charging fees based on how much money clients have invested with them, plus performance fees when funds beat their targets. It operates mainly across Europe, with some reach into global markets, and its edge comes from deep specialist knowledge in healthcare investing — a niche that is harder for generalist competitors to replicate. The main risk the company faces is that assets under management can shrink quickly if markets fall or clients withdraw funds, which directly cuts revenue since fees are tied to the size of those assets.

Winston Score History

Share count broadly stable

+0.1% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 13.3M (2021) → 13.3M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

93.1%

Premium pricing power — 93.1% gross margin

Operating Margin

0.0%

Thin — 0.0% operating margin

ROCE

0.0%

Weak — 0.0% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-9.2%

Shrinking sales (-9.2% YoY)

EPS YoY

+80.7%

Earnings growing fast (+80.7% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency

1/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

216%

Turns 216% of profit into real cash

FCF Margin

13.7%

Converts sales into free cash efficiently (13.7%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.15

Conservative — low debt load (0.15)

Interest Cover

21.66x

Comfortably covers interest (21.7x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

28.5x

Growth-priced — P/E 28.5

P/E above the market average. People are paying up for expected growth.

P/E vs Forward

+22.4

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (28.5 → 6.0)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

2.03%

Moderate income — 2.03% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend Growth

-62.1%

Dividend cut (-62.1% YoY) — warning sign

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial